Recombinant vesicular stomatitis virus vaccine - TFF Pharmaceuticals/United States Army Medical Research Institute of Infectious Diseases
Alternative Names: Filovirus vaccine - TFF Pharmaceuticals; Inhaled vesicular stomatitis virus vaccine - TFF Pharmaceuticals; Viral haemorrhagic fevers vaccine - TFF PharmaceuticalsLatest Information Update: 28 May 2025
At a glance
- Originator TFF Pharmaceuticals
- Developer TFF Pharmaceuticals; United States Army Medical Research Institute of Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Viral haemorrhagic fevers
Most Recent Events
- 03 Mar 2025 Discontinued - Preclinical for Viral haemorrhagic fevers in USA (Inhalation)
- 03 Mar 2025 Discontinued for Viral haemorrhagic fevers in USA (Intranasal)
- 28 May 2024 No recent reports of development identified for preclinical development in Viral-haemorrhagic-fevers in USA (Inhalation, Powder)